Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study-MedSci.cn

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

Mease, PJ; Lertratanakul, A; Papp, KA; van den Bosch, FE; Tsuji, S; Dokoupilova, E; Keiserman, MW; Bu, XW; Chen, L; McCaskill, RM; Zueger, P; McDearmon-Blondell, EL; Pangan, AL; Tillett, W

Mease, PJ (corresponding author), Seattle Rheumatol Associates Swedish Med Ctr, 601 Broadway, Seattle, WA 98122 USA.

Abstract

Introduction Upadacitinib is a Janus kinase inhibitor under investigation in patients with psoriatic arthritis (PsA). This study assessed the 56-week ......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

科室

工具

服务